FDA-2026-P-2079

Requests that the FDA refuse to approve any relugolix ANDA that does not include in its proposed labeling the portions of the ORGOVYX label related to the six-hour dose separation and patient monitoring required upon co-administration of ORGOVYX® and a P-gp inhibitor